Drug
Eptinezumab clinical trials
Also written Vyepti and ALD403.
- studies test it
- 27
- open now
- 7
- in phase 3
- 16
- first study started
- 2013
Keep track of what changes. Save the eptinezumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
27 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 2
- Phase 3
- 16
- Phase 4
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 5
H. Lundbeck A/S (16) · Alder Biopharmaceuticals, Inc. (5) · Danish Headache Center (1) · Dr George Medvedev (1) · Sunnybrook Health Sciences Centre (1) · Stanford University (1) · Rigmor Højland Jensen (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Galcanezumab (2) · Erenumab (2) · Atogepant (1) · Onabotulinum toxin A (1) · Fremanezumab (1)
Studies
Open first, then newest update. How each study uses eptinezumab is read from its arms, and is right about nine times in ten.
Testing it · 27
- Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)Not yet recruitingPhase 3Sunnybrook Health Sciences CentreNCT07191145Written as Eptinezumab
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigraineRecruitingPhase 3H. Lundbeck A/SNCT04965675Written as Eptinezumab
- A Study of Eptinezumab in Pediatric Participants With Episodic MigraineRecruitingPhase 3H. Lundbeck A/SNCT05897320Written as Eptinezumab
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigraineRecruitingPhase 3H. Lundbeck A/SNCT05164172Written as Eptinezumab
- Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency ContextEnrolling by invitationPhase 3Dr George MedvedevNCT06428838Written as Eptinezumab
- Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)Not yet recruitingPhase 4Stanford UniversityNCT07655440Written as Eptinezumab
- Eptinezumab for Chronic Headache in Idiopathic Intracranial HypertensionNot yet recruitingPhase 3Rigmor Højland JensenNCT07645833Written as Eptinezumab
- A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP MedicationsCompletedPhase 4H. Lundbeck A/SNCT06701526Written as Eptinezumab
- A Study of Eptinezumab in Participants With Migraine and Medication Overuse HeadacheCompletedPhase 4H. Lundbeck A/SNCT05452239Written as Eptinezumab
- Eptinezumab as Preventive Treatment of Migraine in Adults With MigraineCompletedPhase 3H. Lundbeck A/SNCT04921384Written as Eptinezumab
- Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in JapanCompletedPhase 3H. Lundbeck A/SNCT05064371Written as Eptinezumab
- A Study of CGRP Monoclonal Antibody to Treat Diabetic NeuropathyWithdrawnPhase 2Mayo ClinicNCT05937152Written as Eptinezumab
- Eptinezumab in Participants With Episodic Cluster HeadacheCompletedPhase 3H. Lundbeck A/SNCT04688775Written as Eptinezumab
- A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)CompletedPhase 3H. Lundbeck A/SNCT05064397Written as Eptinezumab
- Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedPhase 4H. Lundbeck A/SNCT05284019Written as Eptinezumab
- Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.CompletedNot applicableDanish Headache CenterNCT05635604Written as Eptinezumab
- A Study in Children and Young People With Migraine to Learn What the Body Does to EptinezumabCompletedPhase 1H. Lundbeck A/SNCT04537429Written as Eptinezumab
- A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive TreatmentsCompletedPhase 3H. Lundbeck A/SNCT04418765Written as Eptinezumab
- Eptinezumab in Adults With Migraine and Medication Overuse HeadacheCompletedPhase 3H. Lundbeck A/SNCT04772742Written as Eptinezumab
- Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese SubjectsCompletedPhase 1H. Lundbeck A/SNCT05045781Written as Eptinezumab
See all 27 studies that test eptinezumab →
Given in every arm · 1 — eptinezumab is usual care beside what is tested
Codes
What other systems call eptinezumab · ClinicalTrials.gg INT000985
- MeSH (NLM) C000628361eptinezumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8202AY8I7HEPTINEZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2282660One source FDA
- Wikidata Q28208949eptinezumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171835EptinezumabOne source FDA
- DrugBank DB14040One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000628361 | eptinezumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8202AY8I7H | EPTINEZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2282660 | — | One source FDA |
| Wikidata | Q28208949 | eptinezumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171835 | Eptinezumab | One source FDA |
| DrugBank | DB14040 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.